Target- |
MechanismVirus internalization inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismSARS-CoV-2 S protein inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ RecruitingNot Applicable A Multicentric, Prospective Clinical Investigation to Evaluate Microwave Imaging Via MammoWave® in a Population-based Screening Program for Early Breast Cancer Detection to Make Breast Cancer Screening More Accurate, Inclusive, and Female-friendly
This is an open, multicentric, interventional, prospective, non-randomized clinical investigation. The first aim of the study is to confirm that MammoWave reaches sensitivity>75% and specificity>90% in breast cancer (BC) detection on 10.000 volunteers undergoing regular screening programs.
100 Clinical Results associated with Fondazione Toscana Life Sciences
0 Patents (Medical) associated with Fondazione Toscana Life Sciences
100 Deals associated with Fondazione Toscana Life Sciences
100 Translational Medicine associated with Fondazione Toscana Life Sciences